Intellia Therapeutics Inc (NASDAQ:NTLA) price on Thursday, April 10, fall -4.38% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $6.77.
A look at the stock’s price movement, the close in the last trading session was $7.08, moving within a range at $6.365 and $6.91. The beta value (5-Year monthly) was 2.227. Turning to its 52-week performance, $28.18 and $5.90 were the 52-week high and 52-week low respectively. Overall, NTLA moved -29.63% over the past month.
Intellia Therapeutics Inc’s market cap currently stands at around $700.81 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
The average forecast suggests down to a -60.65% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 47.51M, representing a -17.91% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NTLA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
13 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 13 recommend NTLA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NTLA’s current price about -14.83% and -27.36% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 37.23, while 7-day volatility ratio is 14.23% and 9.49% in the 30-day chart. Further, Intellia Therapeutics Inc (NTLA) has a beta value of 2.35, and an average true range (ATR) of 0.79. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $9 and high of $60. Looking at the price targets, the low is -32.94% off current price level while to achieve the yearly target high, price needs to move -786.26%. Nonetheless, investors will most likely welcome a -224.96% jump to $22 which is the analysts’ median price.
If we refocus on Intellia Therapeutics Inc (NASDAQ:NTLA), historical trading data shows that trading volumes averaged 4.61 over the past 10 days and 3.55 million over the past 3 months. The company’s latest data on shares outstanding shows there are 102.03 million shares.
The 5.89% of Intellia Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 90.16% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 26.69 million on 2025-03-14, giving us a short ratio of 7.06. The data shows that as of 2025-03-14 short interest in Intellia Therapeutics Inc (NTLA) stood at 2929.9998 of shares outstanding, with shares short rising to 24.42 million registered in 2025-02-14. Current price change has pushed the stock -41.94% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NTLA stock continues to rise going into the next quarter.
